1. Home
  2. DLPN vs SYBX Comparison

DLPN vs SYBX Comparison

Compare DLPN & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DLPN
  • SYBX
  • Stock Information
  • Founded
  • DLPN 1996
  • SYBX N/A
  • Country
  • DLPN United States
  • SYBX United States
  • Employees
  • DLPN N/A
  • SYBX N/A
  • Industry
  • DLPN Other Consumer Services
  • SYBX Biotechnology: Pharmaceutical Preparations
  • Sector
  • DLPN Consumer Discretionary
  • SYBX Health Care
  • Exchange
  • DLPN Nasdaq
  • SYBX Nasdaq
  • Market Cap
  • DLPN 15.1M
  • SYBX 16.4M
  • IPO Year
  • DLPN N/A
  • SYBX N/A
  • Fundamental
  • Price
  • DLPN $1.50
  • SYBX $1.69
  • Analyst Decision
  • DLPN Strong Buy
  • SYBX
  • Analyst Count
  • DLPN 1
  • SYBX 0
  • Target Price
  • DLPN $5.00
  • SYBX N/A
  • AVG Volume (30 Days)
  • DLPN 53.1K
  • SYBX 17.9K
  • Earning Date
  • DLPN 11-13-2025
  • SYBX 11-11-2025
  • Dividend Yield
  • DLPN N/A
  • SYBX N/A
  • EPS Growth
  • DLPN N/A
  • SYBX N/A
  • EPS
  • DLPN N/A
  • SYBX N/A
  • Revenue
  • DLPN $51,257,243.00
  • SYBX N/A
  • Revenue This Year
  • DLPN $9.05
  • SYBX N/A
  • Revenue Next Year
  • DLPN $15.42
  • SYBX N/A
  • P/E Ratio
  • DLPN N/A
  • SYBX N/A
  • Revenue Growth
  • DLPN 4.84
  • SYBX N/A
  • 52 Week Low
  • DLPN $0.75
  • SYBX $0.90
  • 52 Week High
  • DLPN $1.78
  • SYBX $1.96
  • Technical
  • Relative Strength Index (RSI)
  • DLPN 68.29
  • SYBX 56.21
  • Support Level
  • DLPN $1.25
  • SYBX $1.61
  • Resistance Level
  • DLPN $1.57
  • SYBX $1.74
  • Average True Range (ATR)
  • DLPN 0.07
  • SYBX 0.08
  • MACD
  • DLPN 0.02
  • SYBX -0.01
  • Stochastic Oscillator
  • DLPN 80.00
  • SYBX 41.67

About DLPN Dolphin Entertainment Inc.

Dolphin Entertainment Inc is an independent entertainment marketing and production company. It provides strategic marketing and publicity services to many of the top brands, both individual and corporate, in the motion picture, television, music, gaming, culinary, hospitality, and lifestyle industries. It operates in two reportable segments: Entertainment publicity and marketing and Content production. It generates the majority of its revenue from the Entertainment publicity and marketing segment which provides clients with diversified marketing services, including public relations, entertainment and hospitality content marketing, strategic marketing consulting, and content production of marketing materials.

About SYBX Synlogic Inc.

Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.

Share on Social Networks: